These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29195602)

  • 1. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial.
    Ong SY; Gurrin LC; Dolling L; Dixon J; Nicoll AJ; Wolthuizen M; Wood EM; Anderson GJ; Ramm GA; Allen KJ; Olynyk JK; Crawford D; Ramm LE; Gow P; Durrant S; Powell LW; Delatycki MB
    Lancet Haematol; 2017 Dec; 4(12):e607-e614. PubMed ID: 29195602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron).
    Ong SY; Dolling L; Dixon JL; Nicoll AJ; Gurrin LC; Wolthuizen M; Wood EM; Anderson GJ; Ramm GA; Allen KJ; Olynyk JK; Crawford D; Kava J; Ramm LE; Gow P; Durrant S; Powell LW; Delatycki MB
    BMJ Open; 2015 Aug; 5(8):e008938. PubMed ID: 26270952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
    Kowdley KV; Modi NB; Peltekian K; Vierling JM; Ferris C; Valone FH; Gupta S
    Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1118-1128. PubMed ID: 37863080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis.
    Barton JC; Barton JC; Acton RT; So J; Chan S; Adams PC
    Clin Gastroenterol Hepatol; 2012 Apr; 10(4):412-6. PubMed ID: 22265917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases].
    Poullin P; Lefèvre PA
    Transfus Clin Biol; 2011 Dec; 18(5-6):553-8. PubMed ID: 22019606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
    Rombout-Sestrienkova E; Nieman FH; Essers BA; van Noord PA; Janssen MC; van Deursen CT; Bos LP; Rombout F; van den Braak R; de Leeuw PW; Koek GH
    Transfusion; 2012 Mar; 52(3):470-7. PubMed ID: 21848963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis of 5 patients with possible primary hemochromatosis].
    Jacobs EM; de Vries RA; Elving LD; Stalenhoef AF; Swinkels DW
    Ned Tijdschr Geneeskd; 2003 Apr; 147(14):666-70. PubMed ID: 12712652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HFE p.C282Y homozygosity predisposes to rapid serum ferritin rise after menopause: A genotype-stratified cohort study of hemochromatosis in Australian women.
    Warne CD; Zaloumis SG; Bertalli NA; Delatycki MB; Nicoll AJ; McLaren CE; Hopper JL; Giles GG; Anderson GJ; Olynyk JK; Powell LW; Allen KJ; Gurrin LC;
    J Gastroenterol Hepatol; 2017 Apr; 32(4):797-802. PubMed ID: 27784128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemochromatosis and iron-overload screening in a racially diverse population.
    Adams PC; Reboussin DM; Barton JC; McLaren CE; Eckfeldt JH; McLaren GD; Dawkins FW; Acton RT; Harris EL; Gordeuk VR; Leiendecker-Foster C; Speechley M; Snively BM; Holup JL; Thomson E; Sholinsky P;
    N Engl J Med; 2005 Apr; 352(17):1769-78. PubMed ID: 15858186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI-Based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of Non-Homeostatic Iron Regulator Hemochromatosis Genes.
    Viveiros A; Schaefer B; Panzer M; Henninger B; Plaikner M; Kremser C; Franke A; Franzenburg S; Hoeppner MP; Stauder R; Janecke A; Tilg H; Zoller H
    Hepatology; 2021 Nov; 74(5):2424-2435. PubMed ID: 34048062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum ferritin concentration predicts hepatic fibrosis better than hepatic iron concentration in human HFE-Haemochromatosis.
    Wood MJ; Crawford DHG; Wockner LF; Powell LW; Ramm GA
    Liver Int; 2017 Sep; 37(9):1382-1388. PubMed ID: 28231420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron-overload-related disease in HFE hereditary hemochromatosis.
    Allen KJ; Gurrin LC; Constantine CC; Osborne NJ; Delatycki MB; Nicoll AJ; McLaren CE; Bahlo M; Nisselle AE; Vulpe CD; Anderson GJ; Southey MC; Giles GG; English DR; Hopper JL; Olynyk JK; Powell LW; Gertig DM
    N Engl J Med; 2008 Jan; 358(3):221-30. PubMed ID: 18199861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.
    Sundic T; Hervig T; Hannisdal S; Assmus J; Ulvik RJ; Olaussen RW; Berentsen S
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s84-9. PubMed ID: 24333062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Course of iron parameters in HFE-hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy.
    Rombout-Sestrienkova E; Koek GH; Neslo R; van Kraaij M; Menheere PP; Masclee A; Swinkels DW
    J Clin Apher; 2016 Dec; 31(6):564-570. PubMed ID: 26878994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EASL Clinical Practice Guidelines on haemochromatosis.
    ;
    J Hepatol; 2022 Aug; 77(2):479-502. PubMed ID: 35662478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HFE C282Y homozygosity is associated with lower total and low-density lipoprotein cholesterol: The hemochromatosis and iron overload screening study.
    Adams PC; Pankow JS; Barton JC; Acton RT; Leiendecker-Foster C; McLaren GD; Speechley M; Eckfeldt JH
    Circ Cardiovasc Genet; 2009 Feb; 2(1):34-7. PubMed ID: 20031565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The modified iron avidity index: a promising phenotypic predictor in HFE-related haemochromatosis.
    Verhaegh PL; Moris W; Koek GH; van Deursen CT
    Liver Int; 2016 Oct; 36(10):1535-9. PubMed ID: 26992127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of HFE-related haemochromatosis and secondary causes of hyperferritinaemia and their association with iron overload in 1059 French patients treated by venesection.
    Le Gac G; Scotet V; Gourlaouen I; L'Hostis C; Merour MC; Karim Z; Deugnier Y; Bardou-Jacquet E; Lefebvre T; Assari S; Ferec C
    Aliment Pharmacol Ther; 2022 Apr; 55(8):1016-1027. PubMed ID: 35122291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlates of hepcidin and NTBI according to HFE status in patients referred to a liver centre.
    Ryan E; Ryan JD; Russell J; Coughlan B; Tjalsma H; Swinkels DW; Stewart S; Crowe JP
    Acta Haematol; 2015; 133(2):155-61. PubMed ID: 25277871
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.